A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Main Inclusion Criteria:

- 1. Signed informed consent prior to any study-mandated procedure.

- 2. Male and female subjects aged from 18-85 years, inclusive.

- 3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and
at Visit 2 before randomization.

- 4. Stable CAD defined by the presence of any of the following conditions:

1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.

2. Previously documented myocardial infarction occurring more than 3 months prior to
randomization.

- 5. Antiplatelet background therapy stable for at least 1 month prior to randomization.

- 6. Body weight ≥ 40.0 kg (88.2 lbs).

Main Exclusion Criteria:

- 1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for
peripheral artery disease within 3 months prior to randomization.

- 2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to
randomization.

- 3. Active internal bleeding, or medical history of recent (< 1 month) bleeding
disorders or conditions associated with high risk of bleeding (e.g., clotting
disturbances, gastrointestinal bleed, hemoptysis).

- 4. Hemoglobin ≤ 10 g/dL at screening.

- 5. Loss of at least 250 mL of blood within 3 months of screening.

- 6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior
to screening (Visit 1).

- 7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand
disease).

- 8. Pregnant or breastfeeding women.